ArticleBritish journal of cancer1988
HLA expression in human hepatocellular carcinoma.
Article in British journal of cancer, 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Review
- MHC class I loss is associated with biliary/progenitor cell features and "cold" tumor-immune microenvironment in hepatocellular carcinoma.Virchows Archiv : an international journal of pathology · 2023Article
- Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice.Cancer immunology, immunotherapy : CII · 2022Article
- Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022Review
- Article
- A prognostic risk model based on immune-related genes predicts overall survival of patients with hepatocellular carcinoma.Health science reports · 2020Article
- Article
- Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.Oncotarget · 2020Article
- HCV p7 as a novel vaccine-target inducing multifunctional CD4Scientific reports · 2019Article
- The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.Cancer medicine · 2017Article
- Co-culture of primary human tumor hepatocytes from patients with hepatocellular carcinoma with autologous peripheral blood mononuclear cells: study of their in vitro immunological interactions.BMC gastroenterology · 2013Article
- Expression of class I MHC molecule, HSP70 and TAP in human hepatocellular carcinoma.World journal of gastroenterology · 2003Article
- HLA class I expression in primary hepatocellular carcinoma.World journal of gastroenterology · 2002Article
- HLA-DBR 1 alleles and the susceptibility of Iranian patients with breast cancer.Pathology oncology research : POR · 2001Article
- Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.The Journal of clinical investigation · 1998Article
- HLA expression in hepatocellular carcinoma cell lines.Clinical and experimental immunology · 1994Article
- Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.British journal of cancer · 1994Article
- Human hepatoma cells expressing MHC antigens display accessory cell function: dependence on LFA-1/ICAM-1 interaction.Immunology · 1994Article
- Altered growth of a human neuroendocrine carcinoma line after transfection of a major histocompatibility complex class I gene.Proceedings of the National Academy of Sciences of the United States of America · 1989Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examines the expression of MHC class I and II antigens and their related invariant chains in 70 cases of human hepatocellular carcinoma (HCC), using monoclonal (Mabs) and polyclonal antibodies. In comparison with normal hepatocytes, the majority (94.3%) of HCCs show enhancement or acquisition of HLA-A, B, C in either a cytoplasmic or membranous distribution, with staining being uniformly distributed throughout the specimen. HLA-A, B, C was accompanied by beta 2-microglobulin expression in all but two cases. Although 44.9% of specimens showed HLA-DR expression, positively staining tumour cells were often sparse and heterogeneously distributed. By contrast, the invariant (I) chain, present in 47.1% of cases, was frequently intensively stained and extensive in distribution. HLA-DR staining was usually cytoplasmic although two cases showed faint membranous enhancement. In addition to HLA-DR and I-chain, two cases also showed HLA-DQ staining. Display of MHC antigens was not related to tumour differentiation or size of the lesion (resected vs. advanced tumours). It is possible that the acquisition of class I antigens by the majority of HCCs may influence tumour behaviour.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.